"Yaacov brings many years of business experience in a variety of areas that are relevant to a leading technology transfer company. His background makes him ideal to lead Yissum, as we continue to enhance the commercialization of the Hebrew University's IP, resulting in continued growth of our revenues," stated Dr. Giora Yaron, Chairman of Yissum. "By leveraging existing IP and academic research, while effectively using resources, grants and capital, we will continue to advance and support the University's infrastructure and academic activities and promote the establishment of successful companies based on this research."
Michlin added, "I feel privileged to join Yissum as its CEO and intend to maximize the huge potential of the Hebrew University's IP in diverse areas such as pharmaceuticals, medical devices, cleantech, agriculture, computer science, physics, nanotechnology and more. I am confident that the exceptional quality of the Hebrew University's IP, together with Yissum's outstanding team will continue to deliver results even in these times of crisis."
Over the past twelve years, Yaacov Michlin has been leading and assisting pharmaceutical, hi-tech and biomedical companies in various technology commercialization deals, licensing agreements, capital raising activities, partnerships, mergers and acquisitions. Michlin holds a Bachelor of Law and Economics cum laude, and a Master of Law all from Bar-Ilan University, Ramat Gan, Israel. In addition, he has an MBA cum laude from the Technion Israel Institute of Technology, Haifa, Israel.
About Yissum
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Products based on Hebrew University technologies that have been commercialized by Yissum currently generate $1.2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered 6,100 patents covering 1,750 inventions; has licensed out 480 technologies and has spun-off 65 companies. Yissum’s business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more. For further information please visit www.yissum.co.il.
Contacts Yissum Ltd. Tsipi Haitovsky, +972-52-598-9892 Media Liaison tsipih@yissum.co.il
